Risk factors
Genelux (GNLX) risk factors
Item 1A of every Genelux Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks4 new1 dropped8 reworded
Genelux is advancing its lead immunotherapy candidate, Olvi-Vec, while managing ongoing clinical trials and capital needs.
Filed Mar 19, 2026 - FY2024 10-K risk factors80 risks
Genelux faces substantial ongoing losses and a going concern warning, with its clinical pipeline heavily dependent on its lead oncolytic vaccine candidate, Olvi-Vec.
Filed Mar 28, 2025